Sutro Biopharma to Participate in Upcoming Investor Conferences
Sutro Biopharma, a clinical-stage oncology company, announced that CEO Bill Newell will participate in two upcoming investor conferences. The first is the Piper Sandler 34th Annual Healthcare Conference on November 30, 2022, at 10:30 a.m. ET in New York. The second is the JMP Securities Hematology and Oncology Summit on December 6, 2022, at 3:40 p.m. ET, conducted virtually. Presentations will be accessible on the company’s website for 30 days post-event. Sutro is known for pioneering antibody drug conjugates and currently has two ADCs in clinical trials.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive Officer, will participate in two upcoming investor conferences.
Presentation Details:
Piper Sandler 34th Annual Healthcare Conference
Format: Fireside Chat
Date: Wednesday, November 30, 2022
Time: 10:30 a.m. ET / 7:30 a.m. PT
Location: New York
The JMP Securities Hematology and Oncology Summit
Format: Fireside Chat
Date: Tuesday, December 6, 2022
Time: 3:40 p.m. ET / 12:40 p.m. PT
Location: Virtual
The presentations will be accessible through the News & Events page of the Investor Relations section of the company’s website at www.sutrobio.com. Archived replays will be available for at least 30 days after the events.
About Sutro Biopharma
Sutro Biopharma, Inc., headquartered in South San Francisco, is a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs). Sutro has two wholly owned ADCs in the clinic—STRO-002, a folate receptor alpha (FolRα)-targeting ADC, in clinical studies for ovarian and endometrial cancers; and STRO-001, a CD74-targeting ADC, in clinical studies for B-cell malignancies. Additionally, Sutro is collaborating with Bristol Myers Squibb (BMS) on CC-99712, a BCMA-targeting ADC in the clinic for patients with multiple myeloma; with Merck KGaA, Darmstadt, Germany, known as EMD Serono in the U.S. and Canada (EMD Serono), on M1231, a MUC1-EGFR bispecific ADC in clinical studies for patients with solid tumors, particularly non-small cell lung cancer (NSCLC) and esophageal squamous cell carcinoma; with Merck, known as MSD outside of the United States and Canada, on MK-1484, a selective IL-2 agonist in clinical studies as a monotherapy and in combination with pembrolizumab for the treatment of solid tumors; and with Astellas Pharma (Astellas) on novel modality, immunostimulatory antibody-drug conjugates (iADCs). Sutro’s platform technology also enabled the spin out of Vaxcyte and the creation of VAX-24, a 24-valent pneumococcal conjugate vaccine in clinical studies for the prevention of invasive pneumococcal disease. Sutro’s rational design and precise protein engineering has enabled six product candidates in the clinic. Follow Sutro on Twitter, @Sutrobio, and at www.sutrobio.com to learn more about our passion for changing the future of oncology.
Investor Contact
Annie J. Chang
Sutro Biopharma
(650) 801-5728
ajchang@sutrobio.com
Media Contact
Amy Bonanno
Solebury Strategic Communications
(914) 450-0349
abonanno@soleburystrat.com
FAQ
What is Sutro Biopharma's stock symbol?
When is the Piper Sandler Conference featuring Sutro Biopharma?
What time will Sutro Biopharma present at the JMP Securities Summit?
How can I access Sutro Biopharma's conference presentations?
What antibody drug conjugates is Sutro Biopharma currently developing?
